Neuphoria Therapeutics Inc (NEUP)vsRevolution Medicines Inc (RVMD)
NEUP
Neuphoria Therapeutics Inc
$4.84
+2.98%
HEALTHCARE · Cap: $24.27M
RVMD
Revolution Medicines Inc
$155.69
+4.02%
HEALTHCARE · Cap: $32.71B
Smart Verdict
WallStSmart Research — data-driven comparison
Revolution Medicines Inc generates -5693% more annual revenue ($742,000 vs $-13,267). RVMD leads profitability with a 0.0% profit margin vs 0.0%. NEUP earns a higher WallStSmart Score of 47/100 (D+).
NEUP
Hold47
out of 100
Grade: D+
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Strong operational efficiency at 110513.0%
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NEUP
The strongest argument for NEUP centers on Price/Book, Operating Margin, Debt/Equity.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : NEUP
The primary concerns for NEUP are Revenue Growth, EPS Growth, Market Cap.
Bear Case : RVMD
The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.
Key Dynamics to Monitor
NEUP is growing revenue faster at 0.0% — sustainability is the question.
NEUP generates stronger free cash flow (-4M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NEUP scores higher overall (47/100 vs 24/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Neuphoria Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Neuphoria Therapeutics Inc (Ticker: NEUP) is an innovative biotechnology company at the forefront of developing pioneering therapies for mental health disorders utilizing psychedelic compounds and cutting-edge drug delivery technologies. With a robust pipeline of preclinical candidates, Neuphoria is strategically positioned to address critical unmet needs in mental health care, reflecting the growing demand for effective treatment options in this sector. As a leader in the expanding psychedelic therapy market, Neuphoria presents a unique investment opportunity for institutional investors looking to capitalize on transformative trends in healthcare that have the potential to redefine the treatment landscape for mental health conditions.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?